The INTREPID Alliance is a brand dedicated to accelerating the development of new treatments for emerging viral pandemic agents. Their mission is to ensure the world is better prepared to tackle future viral threats by bridging key gaps and unmet needs in antiviral solutions. Led by the biopharmaceutical industry, INTREPID works with both public and private sectors to coordinate early science and R&D, policy and advocacy, and stakeholder engagement.

The brand focuses on the development of small molecule antivirals, which are crucial to protect societies from new viral pandemics. Unlike vaccines and antibodies, these antiviral drugs can be rapidly mobilized and distributed, are effective against a broad range of viruses, and can change the course of disease even after infection. The INTREPID Alliance also emphasizes public-private partnerships, stakeholder engagement, and policy and advocacy to shape a favorable environment for antiviral development.

With an emphasis on collaboration and innovation, INTREPID is committed to achieving effective pandemic preparedness and preventing future global viral pandemics